Cizzle Bio announced Dr. Ron Greeno, MD, MHM, FCCP, as its new Chief Medical Officer (CMO). With 30 years of experience in healthcare leadership, including physician services management, federal healthcare policy, and value-based care models, Dr. Greeno is a seasoned physician executive and healthcare innovator. His expertise in clinical strategy, policy development, and healthcare payment innovation will be essential in advancing Cizzle Bio’s mission to revolutionize early cancer detection.
Bill Behnke, Cizzle Bio’s Chairman and CEO, shared his enthusiasm about Dr. Greeno’s appointment:
“We are thrilled to welcome Dr. Ron Greeno to Cizzle Bio as our Chief Medical Officer. Having known Dr. Greeno for more than 25 years as an innovator and leader in pulmonary critical care, I am confident that his exceptional background as a seasoned physician executive, healthcare strategist, and clinical thought leader makes him the perfect fit to lead our medical strategy.
With more than three decades of experience across clinical practice, healthcare policy, and value-based care, Dr. Greeno’s deep expertise will be instrumental in expanding strategic partnerships that drive our mission to revolutionize early cancer detection.
His leadership will not only accelerate the adoption of our biomarker-driven diagnostics but also help shape the future of patient-centered care. We are excited about the transformative impact his vision will have on Cizzle Bio’s growth and our ongoing commitment to improving healthcare outcomes for patients worldwide.”
About Dr. Ron Greeno
Dr. Greeno has had a remarkable career, starting with founding Cogent Healthcare, where he served as Executive Vice President for Strategy and Chief Medical Officer until it merged with Sound Physicians. He then took on leadership roles at IPC and TeamHealth, helping to shape hospitalist medicine and physician management across the country.
As a board-certified physician in internal medicine, pulmonary medicine, and critical care, Dr. Greeno has spent his career working to improve patient care, advance healthcare policy, and make healthcare delivery more effective.
In addition to his clinical leadership, Dr. Greeno has played an important role in healthcare policy and government relations:
- He served as Senior Advisor for Government Relations at the Society of Hospital Medicine (SHM).
- He was the former President of SHM, representing 50,000 hospitalist physicians across the country.
- He has worked closely with Capitol Hill, Medicare, and the Center for Medicare and Medicaid Innovation (CMMI).
- His work has focused on innovative healthcare payment models aimed at improving care quality and reducing costs.
In 2003, he received the SHM Award for Outstanding Service in Hospital Medicine. SHM has also awarded him a Master in Hospital Medicine, making Dr. Greeno one of only a hand full of individuals to ever receive this distinction. Three times Modern Healthcare has named Dr. Greeno to its list of the “50 Most Influential Physician Executives” the first hospitalist physician ever to make this prestigious list.
Dr. Greeno’s expertise in value-based care and alternative payment models aligns perfectly with Cizzle Bio’s goal of improving early cancer detection and expanding access to advanced diagnostics.
As Chief Medical Officer, Dr. Greeno will provide strategic medical leadership to help:
- Advance biomarker-driven diagnostics for early cancer detection.
- Navigate reimbursement and healthcare payment models to improve accessibility.
- Expand partnerships with hospitals, payers, and regulatory bodies to promote the adoption of Cizzle Bio’s technologies.
About Cizzle Bio, Inc
Cizzle Bio, Inc. stands at the forefront of biotechnological innovation, dedicated to revolutionizing the detection of lung cancer through groundbreaking diagnostic tools. With exclusive rights to detect the CIZ1B Biomarker in the USA and Canada, we are driven by a commitment to improve early cancer detection and enhance patient outcomes.
